The trend toward reduced survival after AD-EVs compared with SHAM may be associated with a lower content of Fn1 (a protein that interacts with fibrin during the coagulation process) in AD-EVs compared with other EV sources. This evidence concerns the gene FN1 and Alzheimer disease.